Polyphenolic compounds and gut microbiome in cardiovascular diseases.
Onset of cardiovascular disease (CVD) is known to associate with multiple risk factors related to exogenous exposures on predisposed genetic makeup. Individual's diet and lifestyle have a cascade effect on microbiota biodiversity, thus impacting inflammation and heart health. Atherosclerosis is a type of CVD where chronic inflammation contributes to plaque buildup in the arteries resulting in narrowed blood vessels, which obstructs blood flow. Polyphenolic compounds, including flavonoids, are most commonly consumed in the form of plants, have been identified to have various mechanisms of action to reduce inflammatory responses in the body. Flavonoids provide a variety of nutraceutical activities including antioxidant, antimicrobial, anti-inflammatory, antiangiogenic, antitumor, and improved pharmacokinetic properties. Therefore, the medicinal use of polyphenolic compounds as an intervention for inflammatory responses in the body, especially relating to the gut microbiome, may significantly reduce the risk of atherosclerotic plaque development and disease onset. This review attempts to discuss the role of polyphenolic compounds and gut microbiome in cardiovascular diseases. We primarily reviewed studies conducted in cells and animals. These studies clearly illustrate that dietary polyphenolic compounds influences the microbiota makeup associated with atherosclerosis progression and prevention. Further studies in this field are key to potential therapeutic approaches.